Wells Fargo
INKT icon

Wells Fargo’s MiNK Therapeutics INKT Stock Holding History

Wells Fargo’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20
Closed -$223 – 7328
2025
Q4 		$223 Buy
+20
New +$258 ﹤0.01% 6385
2025
Q3 		– Sell
-849
Closed -$6.27K – 7236
2025
Q2 		$6.27K Buy
849
+1
+0.1% +$8 ﹤0.01% 6049
2025
Q1 		$7.33K Sell
848
-160
-16% -$1.43K ﹤0.01% 5955
2024
Q4 		$7.02K Sell
1,008
-45
-4% -$306 ﹤0.01% 6003
2024
Q3 		$7.9K Sell
1,053
-33
-3% -$280 ﹤0.01% 5846
2024
Q2 		$10.3K Sell
1,086
-16
-1% -$156 ﹤0.01% 5731
2024
Q1 		$10K Sell
1,102
-51
-4% -$473 ﹤0.01% 5762
2023
Q4 		$12.3K Sell
1,153
-60
-5% -$626 ﹤0.01% 5778
2023
Q3 		$13.3K Sell
1,213
-1,529
-56% -$24.9K ﹤0.01% 5731
2023
Q2 		$57.6K Buy
2,742
+2,739
+91,300% +$54.9K ﹤0.01% 5365
2023
Q1 		$63 Hold
3
– – ﹤0.01% 7054
2022
Q4 		$84 Hold
3
– – ﹤0.01% 6840
2022
Q3 		$0 Buy
3
+1
+50% +$20 ﹤0.01% 6974
2022
Q2 		$0 Sell
2
-43
-96% -$810 ﹤0.01% 7123
2022
Q1 		$1K Sell
45
-76
-63% -$2.28K ﹤0.01% 6808
2021
Q4 		$5K Buy
+121
New +$14.4K ﹤0.01% 6704

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo's INKT Position: Q1 2026 in Review

Wells Fargo sold out of MiNK Therapeutics (INKT) in Q1 2026, closing a stake of 20 shares — an estimated $223 sold.

Wells Fargo first reported a position in INKT in Q4 2021 and held it in 16 quarters. The position peaked at $57.6K in Q2 2023. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Wells Fargo reported no remaining MiNK Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Wells Fargo sold 20 MiNK Therapeutics shares in Q1 2026, an estimated $223.
  • Wells Fargo first reported a position in MiNK Therapeutics in Q4 2021 and held it in 16 quarters.
  • Wells Fargo's MiNK Therapeutics position peaked at $57.6K in Q2 2023.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.